Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most refractory malignant tumors. Esophageal cancer (EC) is a malignant tumor with a high incidence worldwide, and over 50% of EC cases occur in China. Under the National Comprehensive Cancer Network (NCCN) guidelines, concurrent ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Xiaobin, Zhao, Gang, Liang, Fei, Zhang, Chen, Zhang, Weihong, Liu, Liang, Li, Runmei, Duan, Xiaofeng, Ma, Zhao, Yue, Jie, Chen, Chuangui, Meng, Bin, Ren, Xiubao, Jiang, Hongjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908169/
https://www.ncbi.nlm.nih.gov/pubmed/35280363
http://dx.doi.org/10.21037/atm-22-513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908169/
https://www.ncbi.nlm.nih.gov/pubmed/35280363
http://dx.doi.org/10.21037/atm-22-513

Ejemplares similares